Amongst the increasing number of MDM2 antagonists entering clinical investigation in recent years [16], idasanutlin has progressed furthest with its use in the phase 3 MIRROS trial (NCT02545283) in combination with cytarabine for the treatment of relapsed or refractory acute myeloid leukemia (AML). The gene discussed is MDM2; the disease is acute myeloid leukemia.